ABSTRACT

Nowadays, drug-resistant tuberculosis (DR-TB) and co-infected tuberculosis (CI-TB) strains are the leading cause for the enhancement of long-term morbidity and unpredicted mortality rates from this ghoulish acid fast-bacterium infection, globally. Unfortunately, the lack of/ample lethargic towards the development of compelling anti-TB regimens with a large-scale prevalence rate is a great challenge towards control of the pandemic situation. Indeed, the recent improvement in genomic studies for early diagnosis and understanding the mechanisms of drug resistance, as well as the identification of newer drug targets is quite remarkable and promising. Mainly, identification of such genetic factors, chromosomal mutations and associated pathways gives new ray of hope in current anti-TB drug discovery. This focused review provides molecular insights into the updated drug resistance mechanisms with encoded bacilli genetic factors as a novel target and potential source of development with screened-out newer anti-TB agents towards the control of MDR-TB soon.

摘要

如今，耐药性结核病（DR-TB）和合并感染的结核病（CI-TB）菌株是全球范围内这种可怕的酸性快细菌感染导致长期发病率和意外死亡率增加的主要原因。不幸的是，缺乏/对开发具有大规模流行率的引人注目的抗结核病疗法缺乏嗜睡感是控制大流行情况的巨大挑战。的确，最近在基因组研究方面的改进，用于早期诊断和了解耐药性机制，以及确定新的药物靶标，是非常引人注目的和有希望的。主要是，对这些遗传因素，染色体突变和相关途径的鉴定为当前的抗结核药物发现提供了新的希望。